Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274008 | 1.00 | HSD17B2 (0.39) | HSD17B2POLBHDAC6ADRA1AHRH1 | |
| SCHEMBL4275512 | 0.85 | SMN1; SMN2 (0.35) | HSD17B2POLBADRA1AHRH1ADRA1B | |
| SCHEMBL13572503 | 0.85 | SMN1; SMN2 (0.35) | HSD17B2POLBADRA1AHRH1ADRA1B | |
| SCHEMBL13573331 | 0.84 | HSD17B2 (0.33) | HSD17B2POLBADRA1AHRH1ADRA1B | |
| SCHEMBL4552948 | 0.80 | MAPT (0.42) | HSD17B2POLBHDAC6APLNR | |
| SCHEMBL4277845 | 0.80 | MAPT (0.42) | HSD17B2POLBHDAC6APLNR | |
| SCHEMBL4052973 | 0.73 | SMN1; SMN2 (0.50) | POLBMEN1KMT2A | |
| SCHEMBL13572505 | 0.72 | ALOX12 (0.38) | HDAC6APLNRKMT2A | |
| SCHEMBL4272854 | 0.70 | POLB (0.36) | POLBHDAC6ADRA1AHRH1ADRA1B | |
| SCHEMBL4198917 | 0.69 | RIPK1 (0.40) | POLBRIPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312335-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-12-17 | — | — | US | disclosed |
| US-20090312335-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312335-A1 | Hiv Integrase Inhibitors | RECQL, TYMP, POLR2H | HSD17B2 507/4885POLB 19/4885HDAC6 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.